Search | Clinical Trials Finder

Conditions: Multiple Myeloma
Interventions: Lenalidomide Pill, Dexamethasone, Daratumumab; Drug
Lead sponsor: Attaya Suvannasankha; Other
Eligibility: 65 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Indianapolis, Indiana

Conditions: Multiple Myeloma
Interventions: PHE885; Biological
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 100 Years
Enrollment: 96 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2025
U.S. locations: 4
States / cities: Chicago, Illinois • Boston, Massachusetts • Milwaukee, Wisconsin

Conditions: Bone Marrow Transplantation, Hematopoietic Stem Cells, Multiple Myeloma, Lymphoma
Interventions: Neupogen, Hyperbaric oxygen therapy, Plerixafor; Drug · Procedure
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 21 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Blood Cancer, Multiple Myeloma
Interventions: Autologous hematopoietic cell transplant (Auto-HCT), Allogeneic hematopoietic cell transplant (Allo-HCT), Cyclophosphamide, Filgrastim, Melphalan, Total body irradiation (TBI), Cyclosporine (CSP), Mycophenolate Mofetil (MMF); Procedure · Drug · Radiation
Lead sponsor: Wen-Kai Weng; Other
Eligibility: 18 Years to 70 Years
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2010
U.S. locations: 1
States / cities: Stanford, California

Conditions: MDS
Interventions: APR-246 + azacitidine, Azacitidine; Drug
Lead sponsor: Aprea Therapeutics; Industry
Eligibility: 18 Years and older
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 23
States / cities: Duarte, California • Palo Alto, California • New Haven, Connecticut + 17 more

Conditions: Hemophilia A
Interventions: valoctocogene roxaparvovec; Biological
Lead sponsor: BioMarin Pharmaceutical; Industry
Eligibility: 18 Years and older · Male only
Enrollment: 144 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2024
U.S. locations: 15
States / cities: Los Angeles, California • Sacramento, California • San Diego, California + 12 more

Conditions: Multiple Myeloma
Interventions: Teclistamab, Lenalidomide; Drug
Lead sponsor: European Myeloma Network B.V.; Network
Eligibility: 18 Years and older
Enrollment: 1,594 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2032
U.S. locations: 42
States / cities: Phoenix, Arizona • Los Angeles, California • Sacramento, California + 34 more

Conditions: Cancer
Interventions: cytomegalovirus pp65-specific cytotoxic T lymphocytes, polymerase chain reaction, diagnostic laboratory biomarker analysis, flow cytometry, immunologic technique; Biological · Genetic · Other
Lead sponsor: University of Louisville; Other
Eligibility: 2 Years to 120 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2011
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Hemophilia A
Interventions: single blood draw; Procedure
Lead sponsor: Wyeth is now a wholly owned subsidiary of Pfizer; Industry
Eligibility: Not listed
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 7
States / cities: Atlanta, Georgia • Detroit, Michigan • New Hyde Park, New York + 4 more

Conditions: Advanced Lymphoma, Advanced Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Multiple Myeloma
Interventions: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Echocardiography Test, Magnetic Resonance Imaging, Radionuclide Imaging, Ulixertinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Severe Sepsis
Interventions: Drotrecogin alfa (activated); Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 17
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Fresno, California + 14 more

Conditions: Multiple Myeloma
Interventions: Bendamustine; Drug
Lead sponsor: Loyola University; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Maywood, Illinois

Conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
Interventions: Tocilizumab, Venetoclax; Biological · Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: High-Risk Prostate Cancer
Interventions: Capivasertib, abiraterone acetate; Drug
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 9
States / cities: West Los Angeles, California • Chicago, Illinois • St Louis, Missouri + 6 more

Conditions: Multiple Myeloma
Interventions: Elotuzumab, Lenalidomide, autologous PBMC reconstitution, ASCT; Drug · Other
Lead sponsor: Hearn Jay Cho; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 1
States / cities: New York, New York

Conditions: Breast Cancer, Angiogenesis
Interventions: Aspirin; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years to 95 Years · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Smoldering Multiple Myeloma
Interventions: Carfilzomib, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: International Myeloma Foundation; Other
Eligibility: 18 Years and older
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2031
U.S. locations: 10
States / cities: Tampa, Florida • Chicago, Illinois • Indianapolis, Indiana + 7 more

Conditions: Multiple Myeloma and Plasma Cell Neoplasm
Interventions: pneumococcal polyvalent vaccine, lenalidomide; Biological · Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Multiple Myeloma
Interventions: Idiotype-pulsed allogeneic dendritic cells; Biological
Lead sponsor: Stanford University; Other
Eligibility: 17 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2008
U.S. locations: 1
States / cities: Stanford, California

Conditions: Acute Myeloid Leukemia With FLT3/ITD Mutation, Acute Myeloid Leukemia With Gene Mutations, Acute Myeloid Leukemia With Inv(3) (q21.3;q26.2); GATA2, MECOM, Acute Myeloid Leukemia With t(6;9) (p23;q34.1); DEK-NUP214, Aplastic Anemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelomonocytic Leukemia, Follicular Lymphoma, Hodgkin Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloid Leukemia, Non-Hodgkin Lymphoma, Plasma Cell Myeloma, Polycythemia Vera, Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia
Interventions: Fludarabine phosphate, Busulfan, Total-Body Irradiation, Therapeutic Allogeneic Lymphocytes, Cyclophosphamide, Allogeneic Hematopoietic Stem Cell Transplantation, Peripheral Blood Stem Cell Transplantation, Tacrolimus, Mycophenolate Mofetil, Laboratory Biomarker Analysis; Drug · Radiation · Biological + 2 more
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University; Other
Eligibility: Not listed
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metastatic Bladder Urothelial Carcinoma, Metastatic Malignant Solid Neoplasm, Stage IV Bladder Cancer AJCC v8, MTAP Deletion
Interventions: Biospecimen Collection, Computed Tomography, Pemetrexed; Procedure · Drug
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 2
States / cities: Chicago, Illinois • Orland Park, Illinois

Conditions: Chronic Fatigue Syndrome
Interventions: Nutraceuticals; Drug
Lead sponsor: Columbia University; Other
Eligibility: 20 Years to 70 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Smoldering Multiple Myeloma
Interventions: Selinexor; Drug
Lead sponsor: University of Rochester; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: Rochester, New York

Conditions: Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Ganglioglioma, Anaplastic Meningioma, Anaplastic Oligodendroglioma, Pleomorphic Xanthoastrocytoma, Anaplastic, Atypical Teratoid/Rhabdoid Tumor, Brain Cancer, Brain Tumor, Central Nervous System Neoplasms, Choroid Plexus Carcinoma, CNS Embryonal Tumor With Rhabdoid Features, Ganglioneuroblastoma of Central Nervous System, CNS Tumor, Embryonal Tumor of CNS, Ependymoma, Glioblastoma, Glioma, Glioma, Malignant, Medulloblastoma, Medulloblastoma; Unspecified Site, Medulloepithelioma, Neuroepithelial Tumor, Neoplasms, Neoplasms, Neuroepithelial, Papillary Tumor of the Pineal Region (High-grade Only), Pediatric Brain Tumor, Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only), Pineoblastoma, Primitive Neuroectodermal Tumor, Recurrent Medulloblastoma, Refractory Brain Tumor, Neuroblastoma. CNS, Glioblastoma, IDH-mutant, Glioblastoma, IDH-wildtype, Medulloblastoma, Group 3, Medulloblastoma, Group 4, Glioma, High Grade, Neuroepithelial Tumor, High Grade, Medulloblastoma, SHH-activated and TP53 Mutant, Medulloblastoma, SHH-activated and TP53 Wildtype, Medulloblastoma, Chromosome 9q Loss, Medulloblastoma, Non-WNT Non-SHH, NOS, Medulloblastoma, Non-WNT/Non-SHH, Medulloblastoma, PTCH1 Mutation, Medulloblastoma, WNT-activated, Ependymoma, Recurrent, Glioma, Recurrent High Grade, Glioma, Recurrent Malignant, Embryonal Tumor, NOS, Glioma, Diffuse Midline, H3K27M-mutant, Embryonal Tumor With Multilayered Rosettes (ETMR), Ependymoma, NOS, WHO Grade III, Ependymoma, NOS, WHO Grade II, Medulloblastoma, G3/G4, Ependymoma, RELA Fusion Positive
Interventions: Gemcitabine, ribociclib, sonidegib, trametinib, filgrastim; Drug · Biological
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 1 Year to 39 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Memphis, Tennessee

Search by objective public record fields.

Frailty Score-guided Dosing of Lenalidomide, Dexamethasone and Daratumumab Induction Therapy

BCMA-directed CAR-T Cell Therapy in Adult Patients With Multiple Myeloma

Hyperbaric Oxygen Therapy for Hematopoietic Progenitor Cell Collection in Poor Mobilizers

Non-myeloablative Allogeneic Transplantation for the Treatment of Multiple Myeloma

APR-246 & Azacitidine for the Treatment of TP53 Mutant Myelodysplastic Syndromes (MDS)

Single-Arm Study To Evaluate The Efficacy and Safety of Valoctocogene Roxaparvovec in Hemophilia A Patients (BMN 270-301)

Phase 3 Study of Teclistamab in Combination With Lenalidomide and Teclistamab Alone Versus Lenalidomide Alone in Participants With Newly Diagnosed Multiple Myeloma as Maintenance Therapy Following Autologous Stem Cell Transplantation

Vaccine Therapy in Treating Patients Who Have Undergone a Donor Stem Cell Transplant and Have Cytomegalovirus Infection That Has Not Responded to Therapy

Study Evaluating Inhibitor Specificity in Hemophilia A

Testing BVD-523FB (Ulixertinib) as Potentially Targeted Treatment in Cancers With Genetic Changes (MATCH - Subprotocol Z1L)

Evaluate Protein C Levels in Severe Sepsis Patients on Drotrecogin Alfa (Activated)

Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss

Elotuzumab in Autologous Stem Cell Transplantation (ASCT) and Lenalidomide Maintenance for Multiple Myeloma

The Effect of Aspirin on Angiogenesis Proteins in Women on Tamoxifen Therapy

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma

Vaccine Therapy for Multiple Myeloma Utilizing Idiotype-Pulsed Allogeneic Dendritic Cells

Reduced-Intensity Conditioning Before Donor Stem Cell Transplant in With High-Risk Hematologic Malignancies

Pemetrexed Response in Relation to Tumor Alterations of Gene Status for the Treatment of Patients With Metastatic Urothelial Bladder Cancer and Other Solid Tumors

Therapy for Chronic Fatigue Syndrome: A Presumptive Mitochondrial Disorder

Selinexor for the Treatment of Intermediate and High-Risk Smoldering Multiple Myeloma

SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors